MARKET

DSGN

DSGN

Design Therapeutics, Inc.
NASDAQ
15.40
-0.21
-1.35%
Opening 12:35 05/12 EDT
OPEN
15.67
PREV CLOSE
15.61
HIGH
15.93
LOW
15.36
VOLUME
140.47K
TURNOVER
--
52 WEEK HIGH
17.25
52 WEEK LOW
3.105
MARKET CAP
961.84M
P/E (TTM)
-12.9032
1D
5D
1M
3M
1Y
5Y
1D
Design Therapeutics initiated with an Overweight at Cantor Fitzgerald
TipRanks · 5h ago
Trump approves plan to fire FDA head Marty Makary, CBS reports
TipRanks · 22h ago
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 1d ago
Weekly Report: what happened at DSGN last week (0504-0508)?
Weekly Report · 1d ago
Trump plans to fire FDA commissioner Marty Makary, WSJ reports
TipRanks · 3d ago
Design Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 05/04 18:00
Design Therapeutics Price Target Raised to $21.00/Share From $18.00 by Oppenheimer
Dow Jones · 05/04 18:00
Oppenheimer Maintains Outperform on Design Therapeutics, Raises Price Target to $21
Benzinga · 05/04 17:49
More
About DSGN
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.

Webull offers Design Therapeutics Inc stock information, including NASDAQ: DSGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DSGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DSGN stock methods without spending real money on the virtual paper trading platform.